Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Ferrer

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Pharmacogenetics and Genomics|March 15, 2024
Diversity of oncopharmacogenetic profile within Spanish populationIrene Ferrer Bolufer, Ximo Galiana Vallés, Silvia Izquierdo Álvarez, et al.
The Journal of Pathology|May 21, 2011
Down-regulation of spinophilin in lung tumours contributes to tumourigenesisSonia Molina-Pinelo, Irene Ferrer, Carmen Blanco-Aparicio, et al.
Ebiomedicine|March 2, 2020
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacyÁlvaro Quintanal-Villalonga, Irene Ferrer, Elizabeth Guruceaga, et al.
Nanoscale|May 26, 2022
Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapySergio González-Rubio, Cástor Salgado, Vanesa Manzaneda-González, et al.
Oncotarget|December 30, 2017
Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancerEva M Verdugo-Sivianes, Lola Navas, Sonia Molina-Pinelo, et al.
Cancers|August 28, 2020
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase InhibitorDonatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, et al.
Plos One|March 15, 2014
MicroRNA-dependent regulation of transcription in non-small cell lung cancerSonia Molina-Pinelo, Gabriel Gutiérrez, Maria Dolores Pastor, et al.
Nature Medicine|November 9, 2019
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinomaJun W Kim, Cesar P Marquez, Kaja Kostyrko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2022
YES1 Is a Druggable Oncogenic Target in SCLCEsther Redin, Eva M Garrido-Martin, Karmele Valencia, et al.
Heliyon|January 6, 2025
Telomere-based risk models for the early diagnosis of lung cancerSonia Molina-Pinelo, Irene Ferrer Sánchez, Pilar Najarro, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Pharmacogenetics and Genomics|March 15, 2024
Diversity of oncopharmacogenetic profile within Spanish populationIrene Ferrer Bolufer, Ximo Galiana Vallés, Silvia Izquierdo Álvarez, et al.
The Journal of Pathology|May 21, 2011
Down-regulation of spinophilin in lung tumours contributes to tumourigenesisSonia Molina-Pinelo, Irene Ferrer, Carmen Blanco-Aparicio, et al.
Ebiomedicine|March 2, 2020
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacyÁlvaro Quintanal-Villalonga, Irene Ferrer, Elizabeth Guruceaga, et al.
Nanoscale|May 26, 2022
Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapySergio González-Rubio, Cástor Salgado, Vanesa Manzaneda-González, et al.
Oncotarget|December 30, 2017
Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancerEva M Verdugo-Sivianes, Lola Navas, Sonia Molina-Pinelo, et al.
Cancers|August 28, 2020
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase InhibitorDonatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, et al.
Plos One|March 15, 2014
MicroRNA-dependent regulation of transcription in non-small cell lung cancerSonia Molina-Pinelo, Gabriel Gutiérrez, Maria Dolores Pastor, et al.
Nature Medicine|November 9, 2019
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinomaJun W Kim, Cesar P Marquez, Kaja Kostyrko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2022
YES1 Is a Druggable Oncogenic Target in SCLCEsther Redin, Eva M Garrido-Martin, Karmele Valencia, et al.
Heliyon|January 6, 2025
Telomere-based risk models for the early diagnosis of lung cancerSonia Molina-Pinelo, Irene Ferrer Sánchez, Pilar Najarro, et al.
Pageof 7